Generic CaroSpir Availability
Last updated on Jun 11, 2025.
CaroSpir is a brand name of spironolactone, approved by the FDA in the following formulation(s):
CAROSPIR (spironolactone - suspension;oral)
Is there a generic version of CaroSpir available?
A generic version of CaroSpir has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to CaroSpir and have been approved by the FDA:
spironolactone suspension;oral
-
Manufacturer: AMNEAL
Approval date: September 5, 2023
Strength(s): 25MG/5ML [AB] -
Manufacturer: HETERO LABS LTD III
Approval date: February 21, 2025
Strength(s): 25MG/5ML [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of CaroSpir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Spironolactone aqueous compositions
Patent 10,493,083
Issued: December 3, 2019
Inventor(s): Pipho Anthony & DeHart Michael Paul
Assignee(s): CMP Development LLCDisclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 10,624,906
Issued: April 21, 2020
Inventor(s): Pipho Anthony & DeHart Michael Paul
Assignee(s): CMP Development LLCDisclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 10,660,907
Issued: May 26, 2020
Inventor(s): Pipho Anthony & DeHart Michael Paul
Assignee(s): CMP Development LLCDisclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 10,888,570
Issued: January 12, 2021
Inventor(s): Pipho Anthony & DeHart Michael Paul
Assignee(s): CMP DEVELOPMENT LLCDisclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 11,389,461
Issued: July 19, 2022
Inventor(s): Pipho; Anthony et al.
Assignee(s): CMP DEVELOPMENT LLC (Farmville, NC)Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 11,395,828
Issued: July 26, 2022
Inventor(s): Pipho; Anthony et al.
Assignee(s): CMP DEVELOPMENT LLC (Farmville, NC)Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036✓
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous compositions
Patent 11,491,166
Issued: November 8, 2022
Inventor(s): Pipho; Anthony et al.
Assignee(s): CMP DEVELOPMENT LLC (Farmville, NC)Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Patent expiration dates:
- October 28, 2036✓
- October 28, 2036
-
Spironolactone aqueous formulations
Patent 9,757,394
Issued: September 12, 2017
Inventor(s): Pipho Anthony & DeHart Michael Paul
Assignee(s): CMP DEVELOPMENT LLCDisclosed herein is a pharmaceutical composition, comprising: (a) spironolactone; (b) a xanthan gum; (c) an anti-foaming agent; (d) a preservative; (f) a dispersing agent; (g) a sweetening agent; (h) a flavoring agent; (i) optionally a buffer to maintain the pH of the pharmaceutical composition within a range described herein; and (j) a sufficient amount of a water vehicle.
Patent expiration dates:
- October 28, 2036✓✓
- October 28, 2036
More about CaroSpir (spironolactone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: aldosterone receptor antagonists
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Aldactone
Aldactone (spironolactone) is used to diagnose or treat a condition in which you have too much ...
Triamterene
Triamterene (Dyrenium) is used to treat fluid retention in people with congestive heart failure ...
Acetazolamide
Acetazolamide is used for edema, epilepsy, glaucoma, hydrocephalus, hypokalemic periodic paralysis ...
Bumetanide
Bumetanide is used for ascites, autism, edema, pulmonary edema
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.